These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 23514959)

  • 1. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant development of C1q-positive HLA antibodies and kidney graft survival.
    Piazza A; Poggi E; Ozzella G; Adorno D
    Clin Transpl; 2013; ():367-75. PubMed ID: 25095531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
    Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.
    Willicombe M; Brookes P; Sergeant R; Santos-Nunez E; Steggar C; Galliford J; McLean A; Cook TH; Cairns T; Roufosse C; Taube D
    Transplantation; 2012 Jul; 94(2):172-7. PubMed ID: 22735711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.
    Tagliamacco A; Cioni M; Comoli P; Ramondetta M; Brambilla C; Trivelli A; Magnasco A; Biticchi R; Fontana I; Dulbecco P; Palombo D; Klersy C; Ghiggeri GM; Ginevri F; Cardillo M; Nocera A
    Transpl Int; 2014 Jul; 27(7):667-73. PubMed ID: 24629017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
    Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
    Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of C1q-fixing donor-specific antibodies after kidney transplantation.
    Thammanichanond D; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Worawichawong S; Jirasiritham S; Kitpoka P
    Transplant Proc; 2014; 46(2):368-71. PubMed ID: 24655965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.
    Arnold ML; Ntokou IS; Doxiadis II; Spriewald BM; Boletis JN; Iniotaki AG
    Transpl Int; 2014 Mar; 27(3):253-61. PubMed ID: 24118579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.
    Guidicelli G; Guerville F; Lepreux S; Wiebe C; Thaunat O; Dubois V; Visentin J; Bachelet T; Morelon E; Nickerson P; Merville P; Taupin JL; Couzi L
    J Am Soc Nephrol; 2016 Feb; 27(2):615-25. PubMed ID: 26047793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.
    Wozniak LJ; Hickey MJ; Venick RS; Vargas JH; Farmer DG; Busuttil RW; McDiarmid SV; Reed EF
    Transplantation; 2015 Jul; 99(7):1416-22. PubMed ID: 26038872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor-specific antibody to trans-encoded donor HLA-DQ heterodimer.
    Habig DF; Gaspari JL; Lokhandwala PM; Domen RE; Abendroth CS; Kadry Z; Ghahramani N; Shah RA; Jain A; Shike H
    Hum Immunol; 2015 Aug; 76(8):587-90. PubMed ID: 26382246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
    Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
    Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.